In addition, recent studies have shown that patients treated with ICIs can develop systemic bone loss or localized bone lesions, which are unlikely to be attributed to tumor‐induced osteolysis, suggesting that programmed cell death 1 (PD‐1) blockade may have an impact on the bone remodeling process [27, 28]. The gene discussed is PDCD1; the disease is neoplasm.